Clinical Trial Update: RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial of RRx-001 with platinum doublet in small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Carcinoma

Drugs mentioned

• RRx-001

Snippet

Sponsor: EpicentRx, Inc. | Conditions: Carcinoma, Small Cell Lung | Phase 3 | Status: TERMINATED